ES2138740T3 - Modificacion de toxinas de clostridium utilizadas como proteinas de transporte. - Google Patents

Modificacion de toxinas de clostridium utilizadas como proteinas de transporte.

Info

Publication number
ES2138740T3
ES2138740T3 ES95921007T ES95921007T ES2138740T3 ES 2138740 T3 ES2138740 T3 ES 2138740T3 ES 95921007 T ES95921007 T ES 95921007T ES 95921007 T ES95921007 T ES 95921007T ES 2138740 T3 ES2138740 T3 ES 2138740T3
Authority
ES
Spain
Prior art keywords
modification
transport proteins
toxin
toxins used
clostridium toxins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95921007T
Other languages
English (en)
Inventor
James Oliver Dolly
Kei Roger Aoki
Larry Allen Wheeler
Michael Elwood Garst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9410871A external-priority patent/GB9410871D0/en
Priority claimed from GB9410870A external-priority patent/GB9410870D0/en
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ES2138740T3 publication Critical patent/ES2138740T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/832—Drug, bio-affecting and body treating compositions involving bacterial toxin that has modified amino acid sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE FACILITA UN CONJUGADO QUIMICO PARA TRATAR UNA ENFERMEDAD RELACIONADA CON LAS CELULAS NERVIOSAS. ESTE CONJUGADO INCLUYE UNA TOXINA CLOSTRIDIAL ACTIVA O INACTIVA QUE TIENE ESPECIFICIDAD PARA UNA CELULA NERVIOSA DE DESTINO. LA TOXINA SE CONJUGA EN UN MEDICAMENTO U OTRA MOLECULA BIOACTIVA SIN AFECTAR A LA CAPACIDAD DE LA TOXINA PARA ENTRAR EN LA CELULA NERVIOSA DE DESTINO.
ES95921007T 1994-05-31 1995-05-31 Modificacion de toxinas de clostridium utilizadas como proteinas de transporte. Expired - Lifetime ES2138740T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9410871A GB9410871D0 (en) 1994-05-31 1994-05-31 Modification of tetanus toxin for use as a transport protein
GB9410870A GB9410870D0 (en) 1994-05-31 1994-05-31 Modification of botulinum toxins for use as transport proteins

Publications (1)

Publication Number Publication Date
ES2138740T3 true ES2138740T3 (es) 2000-01-16

Family

ID=26304971

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95921007T Expired - Lifetime ES2138740T3 (es) 1994-05-31 1995-05-31 Modificacion de toxinas de clostridium utilizadas como proteinas de transporte.

Country Status (9)

Country Link
US (1) US6203794B1 (es)
EP (1) EP0760681B1 (es)
JP (1) JP3523879B2 (es)
AU (1) AU695623B2 (es)
CA (1) CA2191754C (es)
DE (1) DE69511860T2 (es)
DK (1) DK0760681T3 (es)
ES (1) ES2138740T3 (es)
WO (1) WO1995032738A1 (es)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7227010B2 (en) 1993-09-21 2007-06-05 United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US7214787B1 (en) * 1993-09-21 2007-05-08 United States Of America As Represented By The Secretary Of The Army Recombinant vaccine against botulinum neurotoxin
US6967088B1 (en) * 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
GB9524807D0 (en) * 1995-12-05 1996-02-07 Smithkline Beecham Plc Novel compounds
US6169074B1 (en) 1996-03-18 2001-01-02 The Regents Of The University Of California Peptide inhibitors of neurotransmitter secretion by neuronal cells
US6444209B1 (en) 1996-10-28 2002-09-03 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
US5939070A (en) * 1996-10-28 1999-08-17 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
GB9721189D0 (en) * 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
US6051239A (en) * 1997-10-20 2000-04-18 Thomas Jefferson University Compositions and methods for systemic delivery of oral vaccines and therapeutic agents
AU2340299A (en) * 1998-01-26 1999-08-09 University Of Massachusetts Biologically active hemagglutinin from type a (clostridium botulinum) and methods of use
DE19856052A1 (de) * 1998-12-04 2000-06-08 Deutsches Krebsforsch Konjugat zur Anreicherung in neuronalen Zellen
US6652864B1 (en) * 1998-12-21 2003-11-25 Asilomar Pharmaceuticals, Inc. Compounds for intracellular delivery of therapeutic moieties to nerve cells
US20040120891A1 (en) 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
GB9907429D0 (en) 1999-03-31 1999-05-26 Microbiological Res Authority Modulation of C-fibre activity
US6776990B2 (en) 1999-04-08 2004-08-17 Allergan, Inc. Methods and compositions for the treatment of pancreatitis
JP2003508092A (ja) * 1999-08-20 2003-03-04 インペリアル・カレッジ・イノベイションズ・リミテッド 細胞エキソサイトーシスの調節におけるｓｎａｒｅ分子のイソフォーム及びその使用
EP1206554B2 (en) 1999-08-25 2010-10-20 Allergan, Inc. Activatable recombinant neurotoxins
US7740868B2 (en) 1999-08-25 2010-06-22 Allergan, Inc. Activatable clostridial toxins
US6641820B1 (en) 2000-01-19 2003-11-04 Allergan, Inc. Clostridial toxin derivatives and methods to treat pain
US6500436B2 (en) 2000-01-19 2002-12-31 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US7138127B1 (en) 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US6670322B2 (en) * 2000-06-01 2003-12-30 Wisconsin Alumni Research Foundation Method of targeting pharmaceuticals to motor neurons
DE10035156A1 (de) * 2000-07-19 2002-02-07 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Proteinkomplex als Vehikel für oral verfügbare Protein-Arzneimittel
US6423319B1 (en) 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
DE60130266D1 (de) * 2000-11-06 2007-10-11 Us Army Med Res Mat Command Rekombinante leichte kette des botolinum neurotoxins and fusionsproteine davon zur verwendung in forschung und klinischer therapie
US7273722B2 (en) 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
US6787517B1 (en) * 2000-12-29 2004-09-07 Allergan, Inc. Agent and methods for treating pain
WO2002086131A1 (fr) * 2001-04-09 2002-10-31 Gencom Corporation Unite de regulation de l'expression genetique et utilisation de cette unite
JP4707254B2 (ja) * 2001-04-24 2011-06-22 クミアイ化学工業株式会社 粒状組成物及びその製造方法
GB0112687D0 (en) * 2001-05-24 2001-07-18 Microbiological Res Authority Pharmaceutical use of secreted bacterial effector proteins
JP2003009897A (ja) 2001-07-03 2003-01-14 Keiji Oguma ボツリヌス毒素の分離・精製法
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
NZ537120A (en) * 2002-05-31 2008-07-31 Univ Jefferson Compositions and methods for transepithelial molecular transport
US6776991B2 (en) * 2002-06-26 2004-08-17 Allergan, Inc. Methods for treating priapism
AU2003272800A1 (en) 2002-10-01 2004-04-23 University Of Maryland Methods for identifying inhibitors of botulinum neurotoxins
US20040115727A1 (en) * 2002-12-11 2004-06-17 Allergan, Inc., A Corporation Evolved clostridial toxins with altered protease specificity
BR0316871A (pt) * 2002-12-20 2005-10-18 Botulinum Toxin Res Ass Inc Composições farmacêuticas aperfeiçoadas de toxina botulìnica
JP2007070225A (ja) * 2003-07-25 2007-03-22 Yukako Fujinaga クロストリジウム属菌由来成分を含む医薬製剤
US7172764B2 (en) * 2003-11-17 2007-02-06 Allergan, Inc. Rescue agents for treating botulinum toxin intoxications
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
CA2588758C (en) * 2004-11-22 2017-01-03 New York University Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof
DE102005019302A1 (de) * 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
DK1926744T4 (en) * 2005-09-19 2019-01-28 Allergan Inc CLOSTRIDIUM TOXIN-ACTIVABLE CLOSTRIDIAL TOXINES
EP2041162A2 (en) 2006-07-11 2009-04-01 Allergan, Inc. Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity
CA2658260A1 (en) 2006-07-11 2008-01-17 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
WO2009038770A2 (en) * 2007-09-20 2009-03-26 University Of Massachusetts Cvip Detoxified recombinant botulinum neurotoxin
WO2009131435A1 (en) * 2008-04-23 2009-10-29 Erasmus University Medical Center Rotterdam Linker containing bungarotoxin and a binding peptide
WO2010096134A1 (en) 2008-12-04 2010-08-26 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
US8492109B2 (en) * 2009-01-20 2013-07-23 Trustees Of Tufts College Methods for the delivery of toxins or enzymatically active portions thereof
EP2218783A1 (en) 2009-02-05 2010-08-18 Merz Pharma GmbH & Co. KGaA Novel method for the manufacturing of neurotoxins
US20120244188A1 (en) * 2011-03-25 2012-09-27 Allergan, Inc. Treatment of Sensory Disturbance Disorders
US20140377248A1 (en) 2011-12-23 2014-12-25 Merz Pharma Gmbh & Co. Kgaa Method for the manufacturing of di-chain proteins for use in humans
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
SG11201407784UA (en) 2012-05-30 2014-12-30 Harvard College Engineered botulinum neurotoxin
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
JP2016513082A (ja) 2013-01-28 2016-05-12 ニューヨーク・ユニバーシティ 無毒性神経毒誘導体を用いる治療方法
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
WO2015132004A1 (en) 2014-03-05 2015-09-11 Merz Pharma Gmbh & Co. Kgaa Novel recombinant clostridial neurotoxins with increased duration of effect
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US11897921B2 (en) 2014-12-09 2024-02-13 New York University Propeptide fusion comprising a mutated clostridium botulinum neurotoxin and a VHH domain
WO2016097243A1 (en) 2014-12-19 2016-06-23 Merz Pharma Gmbh & Co. Kgaa Means and methods for the determination of the biological activity of bont/e in cells
US11268080B2 (en) 2015-03-26 2022-03-08 President And Fellows Of Harvard College Engineered botulinum neurotoxin
TW201718627A (zh) 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
ES2929347T3 (es) 2016-01-20 2022-11-28 Merz Pharma Gmbh & Co Kgaa Nuevas neurotoxinas clostridiales recombinantes con aumento de la duración del efecto
AU2017227978B2 (en) 2016-03-02 2022-03-10 Merz Pharma Gmbh & Co. Kgaa Composition comprising botulinum toxin
US11117935B2 (en) 2016-08-24 2021-09-14 President And Fellows Of Harvard College Engineered botulinum neurotoxin
EP3290437A1 (en) 2016-08-31 2018-03-07 Merz Pharma GmbH & Co. KGaA Novel recombinant clostridial neurotoxins with decreased duration of effect
HRP20191966T4 (hr) 2016-09-13 2022-09-16 Allergan, Inc. Stabilizirani neproteinski klostridijalni pripravci toksina
EP3312193A1 (en) 2016-10-19 2018-04-25 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with accelerated onset of effect
WO2018075783A2 (en) 2016-10-20 2018-04-26 President And Fellows Of Harvard College In vitro and cell based assays for measuring the activity of botulinum neurotoxins
EP3333179A1 (en) 2016-12-07 2018-06-13 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum toxin with accelarated onset of effect
EP3335719A1 (en) 2016-12-14 2018-06-20 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with a stabilized light chain
US11952601B2 (en) 2017-06-20 2024-04-09 Merz Pharma Gmbh & Co. Kgaa Recombinant botulinum toxin with increased duration of effect
ES2930237T3 (es) 2017-07-06 2022-12-09 Merz Pharma Gmbh & Co Kgaa Neurotoxinas botulínicas recombinantes nuevas con mayor duración de efectos
EP3700919A1 (en) 2017-10-26 2020-09-02 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with increased duration of effect
WO2019101308A1 (en) 2017-11-22 2019-05-31 Merz Pharma Gmbh & Co. Kgaa Novel recombinant botulinum toxin with increased duration of effect
JP2021530507A (ja) 2018-07-18 2021-11-11 マンザニータ ファーマシューティカルズ，インク． 神経細胞に抗がん剤を送達するためのコンジュゲート、その使用方法及び製造方法
WO2023105289A1 (en) 2021-12-06 2023-06-15 Dublin City University Methods and compositions for the treatment of pain

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4594336A (en) * 1982-09-28 1986-06-10 Institut Pasteur Thiolated polypeptide compound derived from a tetanus toxin fragment, the process for obtaining and its application
US4713240A (en) * 1985-04-04 1987-12-15 Research Corporation Vaccines based on insoluble supports
US5204097A (en) * 1986-07-06 1993-04-20 Yeda Research And Development Company Limited Shiga toxin B chain polypeptides and vaccine thereto
IL79346A0 (en) 1986-07-06 1986-10-31 Yeda Res & Dev Shiga vaccine
US5919665A (en) * 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
US5599539A (en) * 1989-10-31 1997-02-04 Ophidian Pharmaceuticals, Inc. Therapy for clostridial botulinum toxin
US5736139A (en) * 1989-10-31 1998-04-07 Ochidian Pharmaceuticals, Inc. Treatment of Clostridium difficile induced disease
US5719267A (en) * 1989-10-31 1998-02-17 Ophidian Pharmaceuticals Inc. Clostridial toxin disease therapy
US5601823A (en) * 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
US5196193A (en) * 1989-10-31 1993-03-23 Ophidian Pharmaceuticals, Inc. Antivenoms and methods for making antivenoms
NZ249704A (en) * 1992-02-11 1996-11-26 Jackson H M Found Military Med A two carrier immunogenic construct comprising a 70+ kd molecule conjugated to at least 1 t-dependent antigen, preparation, compositions containing the construct
CA2138020C (en) * 1992-06-23 1999-02-16 Eric A. Johnson Pharmaceutical composition containing botulinum b complex
WO1994000487A1 (en) * 1992-06-30 1994-01-06 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Peptide which produces protective immunity against tetanus
US5562907A (en) * 1993-05-14 1996-10-08 Arnon; Stephen S. Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US5512547A (en) * 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US5693476A (en) * 1995-02-24 1997-12-02 The Board Of Trustees Of The Leland Stanford Junior University Methods of screening for compounds capable of modulating vesicular release
US5650280A (en) * 1995-03-23 1997-07-22 Incyte Pharmaceuticals, Inc. Cellubrevin homolog
US5721215A (en) * 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
US5965699A (en) * 1996-11-06 1999-10-12 The United States Of America As Represented By The Secretary Of The Army Assay for the proteolytic activity of serotype a from clostridium botulinum
US5955368A (en) * 1998-04-06 1999-09-21 Wisconsin Alumni Research Foundation Expression system for clostridium species

Also Published As

Publication number Publication date
US6203794B1 (en) 2001-03-20
AU695623B2 (en) 1998-08-20
CA2191754C (en) 2000-12-12
AU2622295A (en) 1995-12-21
WO1995032738A1 (en) 1995-12-07
EP0760681A1 (en) 1997-03-12
JPH10500988A (ja) 1998-01-27
DE69511860T2 (de) 2000-02-10
DK0760681T3 (da) 2000-03-27
DE69511860D1 (de) 1999-10-07
CA2191754A1 (en) 1995-12-07
EP0760681B1 (en) 1999-09-01
JP3523879B2 (ja) 2004-04-26

Similar Documents

Publication Publication Date Title
ES2138740T3 (es) Modificacion de toxinas de clostridium utilizadas como proteinas de transporte.
ES2074042T3 (es) Exotoxina recombinante de pseudomonas construccion de una inmunotoxina activa con efectos secundarios menores.
ES2032755T3 (es) Medicamentos conteniendo hexadecil-fosfocolina con efecto antitumoral.
YU46978B (sh) Postupak za dobijanje preparata za nazalnu upotrebu
DE3684398D1 (de) Lipolytische enzyme und deren anwendung in reinigungsmitteln.
DE69814858D1 (de) Galaktose-bindende lektine konjugate mit clostridiale neurotoxine ,wie analgetika
BR9509269A (pt) Processo para tratar diabetes
ES2088425T3 (es) Metodo de produccion de xilitol a partir de mezclas que contienen xilosa.
DE60008915D1 (de) Konstrukte zur verabreichung von therapeutischen wirkstoffen an die neuronzellen
ES8607722A1 (es) Un procedimiento para preparar una solucion oftalmica
PT1318198E (pt) Processo para produzir um polipeptido recombinante que envolve a adicao de um inibidor de quimotripsina ao meio de cultura celular
ES2014429B3 (es) Nuevas 4-triazol-4,3-a 1,4-benzodiazepinas, procedimiento para su preparacion, su aplicacion como medicamentos y preparaciones que las contienen.
ES2134924T3 (es) Acidos sulfonilalcanoilamino-hidroxietilamino-sulfamicos utiles como inhibidores de proteasas retrovirales.
ES2080037T3 (es) Medicamento de uso topico con actividad cicatrizante.
BR9810267A (pt) Preparados de combinações farmacêuticas, processo para a produção dos mesmos, utilização de preparados de eritropoietina e embalagem unitária farmacêutica
TR200001486T2 (tr) Hiperkeratozlu deri hastalıklarının tedavisi için diol ve alfa-hidroksi asitten oluşan bir karışımın kullanılması
ES2195040T3 (es) Conjugado que incluye un principio activo, un polipeptido y varios polieteres y su uso como medicamento.
ES2043696T3 (es) Derivados de prostaglandina e1 (derivados-pge1) como substancias activas farmaceuticas y medicamentos que contienen estos compuestos, especialmente para aplicacion transcutanea.
AR011238A1 (es) Composicion que consiste esencialmente de toxina gbs (bacterias streptococcus beta-hemoliticos del grupo b), composicion farmaceutica, metodode purificacion de dicha toxina, toxina obtenida mediante dicho metodo y uso de dicha toxina para preparar composiciones farmaceuticas
DE58906338D1 (de) Kombination von Angiotensin-Converting-Enzyme-Hemmern mit Kaliumkanal-Modulatoren sowie deren Verwendung in Arzneimitteln.
ES2044842T3 (es) Matriz de soporte de colageno topico biologicamente activo, usos cosmeticos y farmaceuticos y un procedimiento para su preparacion.
WO2000033880A3 (de) Konjugat zur anreicherung in neuronalen zellen
ES2172060T3 (es) Sistema de rectificacion criogenica con una columna dividida para producir oxigeno con diferentes purezas.
CO4410254A1 (es) Procedimiento para introducir material extrano en celulas eucarioticas superiores
SE8100623L (sv) Topiskt, indomentacinhaltigt lekemedel

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 760681

Country of ref document: ES